A Phase IIa trial for VG-08182-AC in non‑alcoholic steatohepatitis (NASH) treatment
Latest Information Update: 24 Mar 2026
At a glance
- Drugs VG 081821 AC (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Zhejiang Vimgreen Pharmaceuticals
Most Recent Events
- 24 Mar 2026 New trial record
- 14 Mar 2026 According to Zhejiang Vimgreen Pharmaceuticals media release, the company expects to initiate the trial in the second half of the year.